US patent issued to Metabolon for methods to determine human
20 Sept 2010
Metabolon, Inc., has been awarded a US patent for chemical
markers and methods to determine the metabolic age of humans.
This is the twelfth patent issued to the company. Metabolon is the
exclusive license holder of the Daouk-Kristal patent family which is
comprised of early, pioneering patents and patent applications which
provide fundamental intellectual property in the field of
As more information regarding the impact of nutrition on
health-related issues becomes available and as the population ages,
interest in health and nutrition has increased. The metabolism of an
individual changes with age. Until recently the ability to monitor
metabolite changes has been limited to targeted assays.
With the development of metabolomics analysis, changes in
metabolites can now be monitored globally in a non-targeted manner.
This metabolomic approach allows a metabolic profile to be
determined for a group or an individual.
The ability to determine the metabolite levels of an individual
and classify the resulting metabolic profile as positive or negative
and then to provide guidance as to how to improve a negative profile
will have beneficial effects on the health of an individual.
Metabolon’s previously issued patents include the use of
metabolomics for determining biomarkers for disease, including
cancer, metabolic disorders, and neurological disorders such as
Amyotrophic Lateral Sclerosis (ALS), Alzheimer's Disease,
Parkinson's Disease, Huntington's Disease, depression and
schizophrenia, and for evaluating chemical agents for therapeutic
effects and toxicity. Metabolon also owns patents relating to
software designed for analyzing metabolomics data.